Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
HQL6 serves as a novel P2Y14 receptor antagonist to ameliorate acute gouty arthritis through inhibiting macrophage pyroptosis — Mengze Zhou (2022) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
HQL6 serves as a novel P2Y14 receptor antagonist to ameliorate acute gouty arthritis through inhibiting macrophage pyroptosis
ZZ
Shared by
Zhenguo Zhang
HQL6 serves as a novel P2Y14 receptor antagonist to ameliorate acute gouty arthritis through inhibiting macrophage pyroptosis
Article
2022
en
Authors
+6 more
MZ
Mengze Zhou
CL
Chunxiao Liu
YG
Yanshuo Guo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2021
Targeting CAMKK2 and SOC Channels as a Novel Therapeutic Approach for Sensitizing Acute Promyelocytic Leukemia Cells to All-Trans Retinoic Acid
Faten Merhi
,
Karla Alvarez-Valadez
,
Jenifer Trepiana
,
Claire Lescoat
,
Alexis Groppi
,
Jean‐William Dupuy
,
Pierre Soubeyran
,
Guido Guido Kroemer
,
Pierre Vacher
,
Mojgan Djavaheri‐Mergny
Article
1999
A Novel Element Upstream of the Vγ2 Gene in the Murine T Cell Receptor γ Locus Cooperates with the 3′ Enhancer to Act as a Locus Control Region
Jeanne E. Baker
,
Joonsoo Kang
,
Na Xiong
,
Tempe Chen
,
Dragana Cado
,
David H Raulet
Article
2024
MiR-106a-5p targets PFKFB3 and improves sepsis through regulating macrophage pyroptosis and inflammatory response
Yixin Chen
,
Ping Zhang
,
Fangwei Han
,
Yanying Zhou
,
Jue-Xian Wei
,
Cailing Wang
,
Mingchuan Song
,
Shao-Peng Lin
,
Yiming Xu
,
Xiaohong Chen
Journal of Biological Chemistry
Article
2000
Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function
Holger S. Willenberg
,
Stefan R. Bornstein
,
Naoki Hiroi
,
G Päth
,
Peter E. Goretzki
,
Werner A. Scherbaum
,
George Chrousos
Article
2017
A photoactivatable photochromic system serves as a self-hidden information storage material
Yuanyuan Li
,
Kai Li
,
Ben Zhong Tang
Discussion(0)
No comments yet. Be the first to comment.